Please login to the form below
United Therapeutics
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of United Therapeutics' 2013 cardiovasular sales performance.
Rare disease therapies head the ‘class of 2015’
have a treatment option in the form of Wellstat Therapeutics' Xuriden (uridine triacetate). ... USA. dinutuximab. Unituxin. neuroblastoma. anti-GD2 antibody. United Therapeutics. USA. elotuzumab. Empliciti.
FDA approvals hit 19-year high
Orkambi (ivacaftor plus lumacaftor) and United Therapeutics' paediatric bran cancer therapy Unituxin (dinutuximab).
Actelion claims first approval for PAH therapy Uptravi
Uptravi will compete in the US marketplace with another oral prostacyclin agonist - United Therapeutics' Orenitram (treprostinil) - and Actelion is banking that the data behind its new drug will allow it to
GSK earns expanded approval for Volibris in Europe
s Adempas (riociguat) and United Therapeutics' Orenitram (trepostinil).
Gilead receives FDA approval for PAH combo
Additionally there will be competition from Bayer's Adempas (riociguat), which was cleared by the FDA in 2013, and United Therapeutics' Remodulin (treprostinil).
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
IPG Health Medical Communications
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
